



The future of lung health

4DMedical Limited (ASX:4DX)
Extraordinary General Meeting
22 January 2024

4DMedical Limited ABN 31 161 684 831



Disclaimer

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 22 January 2024 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

Overview



Agenda

- 1. Opening & introductions**
- 2. Chair's address**
- 3. CEO address**
- 4. Procedural matters**
- 5. Formal business**
- 6. Closing remarks**

Board of Directors

Significant medical and commercial sector experience



LIL BIANCHI

Non-Executive Chair

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ANDREAS FOURAS PhD

Managing Director and CEO

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



Dr ROBERT A. FIGLIN MD

Non-Executive Director

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.



Dr GERALDINE MCGINTY MD

Non-Executive Director

Internationally recognized expert in health care strategy and imaging economics, and prominent advocate for patient-centered care. A Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs.



JULIAN SUTTON

Non-Executive Director

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



JOHN LIVINGSTON

Executive Director

Founding partner of ASX listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings.

Key advisors

Medical experts



Dr SAM HUPERT MBBS
Advisory Board Member

Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia.



Prof BRUCE THOMPSON PhD
Advisory Board Member

Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital.



Dr DAVID J. SHULKIN MD
Key Advisor

Highly respected physician and health care executive, Dr Shulkin was previously the Secretary of the United States Department of Veterans Affairs (VA). As Secretary of the VA, Dr Shulkin oversaw the US government's second largest agency, with over 350,000 employees and 1,700 facilities, serving over 9 million Veterans.

Chair's address



LIL BIANCHI Non-Executive Chair

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.




Chief Executive Officer



Dr ANDREAS FOURAS PhD
Managing Director

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



4DMedical Limited (ASX:4DX) - introduction

➤ Who is 4DMedical:


- Software technology company commercialising its patented imaging platform, XV Technology®
- Allows physicians to diagnose, treat and manage patients more effectively, more efficiently and at lower cost than existing modalities
- Developed first dedicated lung scanner to utilise XV Technology®

➤ The opportunity:

- Respiratory diseases represent ~17%¹ of all global deaths, resulting in an economic burden of over US\$173b¹
- **Almost US\$14b is spent on respiratory diagnostics each year in the US alone across more than 73m procedures¹**
- US PACT ACT signed in 2022 represents an additional US\$280bn in additional funding over 10 years for US Veterans exposed to airborne hazards

➤ The business model:

- Utilises existing diagnostics equipment through a cloud-based Software as a Services (SaaS) model
- 90%+ Gross Margins on XV Technology® software
- Pre-agreed pricing structure with Veterans Affairs of US\$171 per scan
- US Center for Medicare and Medicaid Services (CMS) has assigned US\$299 as reimbursement benefit for XV LVAS® - will accelerate adoption of XV Technology®




XV Technology[®] advantages




New medical insights

Functional insight of spirometry at a regional level



Improved safety

Comparable radiation dose to X-ray



Superior results

High-detail resolution of a CT scan



Patient outcomes

Improved clinical outcomes



Time efficient

Faster, more efficient testing using existing hardware



Low cost

Competitive pricing below incumbent technologies



XV Technology[®] 4D view of lung performance

Material acceleration in commercialisation across 2Q FY2024, with Imbio acquisition a step change

Objective: Become the standard of care for lung diagnosis across both ventilation and perfusion



Philips collaboration established with signing of Teaming Agreement

➤ Details:

- Focus of the agreement will be to offer 4D lung imaging as a critical screening solution for Veterans exposed to burn pits.
- Combined commercial product solutions from Philips and 4DMedical provided to VA through Philips Government sales team.
- Philips has a long established and significant existing partnership with both the VA and DoD:
 - 45-year relationship;
 - 35% of the critical care information systems across the VA; and
 - 50% of VA clinics use Philips imaging solutions.
- Subsequently, intent is to expand access to both software and hardware solutions, including to other US based Federal agencies and commercial organisations in North America.
- The parties will also consider other markets outside of North America for expansion.



PHILIPS

Imbio acquisition highlights

Function + Structure 'Owning the lung'

Additional 4 lung diagnostic products, resulting in a full suite of products providing a comprehensive lung offering

Commercialisation

Deliver XV Technology® into established Imbio contracts, accelerating US commercialisation

Growth opportunity

Potential to provide screening program offerings across COPD, heart disease and lung cancer* in AU and US markets

US Veterans Health Administration

Established agreements;
Complementary relationships;
Compelling product range for comprehensive diagnostics for screening programs

Revenue contribution from long-term contracts at high gross margin

CY2024 expected revenue contribution US\$6.3 million;
Adjacent markets and customers in pharma and device
Gross margin +84%

Strong strategic benefits


Revenue and cost synergies;
Complementary products in adjacent markets & customers;
Extends reach of 4DX's products;
Platform and technology efficiencies

Summary – substantial progress in commercialisation


- Reimbursement of XV ahead of schedule with increased payment and removes largest barrier to commercialisation in US
- FDA approval of CT LVAS™ - expansion into US, following Australian model
- Philips agreement leverages scalability, relationships and contracts, with initial focus on VA, growing across US and globally
- Imbio acquisition synergistically interacts with all facets of commercialization:
 - Function combined with structure for a comprehensive offering
 - Expands and accelerates VA opportunities through additional products and relationships
 - Revenue from long-term contracts at high gross margin
 - Revenue and cost synergies, platform and technology synergies



Procedural matters



Formal business



Items of Business

- Item 1:** Ratification of issue of Shares under the Placement

- Item 2:** Approval for the proposed issue of New Options under the Placement

- Item 3:** Approval for the proposed issue of Earn Out Shares

- Item 4:** Approval for the proposed issue of Options to Director in lieu of base directors' fees – Dr Geraldine McGinty

- Item 5:** Approval for the proposed issue of Options to Director in lieu of base directors' fees – Ms Lilian Bianchi

- Item 6:** Approval for the renewal of the 4DMedical Limited Long Term Incentive Plan and the proposed issue of securities under the plan

Formal business

Item 1: Ratification of issue of Shares under the Placement

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of Shares under the Placement on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
72,132,480	403,880	2,934,378	260,408
95.58%	0.54%	3.89%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 1.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 2: Approval for the proposed issue of New Options under the Placement

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, in accordance with Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue of New Options under the Placement on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
70,496,509	3,568,259	1,434,378	232,000
93.37%	4.73%	1.90%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 3: Approval for the proposed issue of Earn Out Shares

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, in accordance with Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue of the Earn Out Shares on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
82,372,393	1,482,297	2,954,694	185,286
94.89%	1.71%	3.40%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 3.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 4: Approval for the proposed issue of Options to Director in lieu of base directors' fees – Dr Geraldine McGinty

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 40,000 Options to Dr Geraldine McGinty (or her nominee) on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
19,198,888	1,269,167	1,600,890	19,698
87.00%	5.75%	7.25%	

Further Information:

- The Board (other than Dr Geraldine McGinty) unanimously recommends that Shareholders vote in favour of Item 4.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 5: Approval for the proposed issue of Options to Director in lieu of base directors' fees – Ms Lil Bianchi

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 40,000 Options to Dr Geraldine McGinty (or her nominee) on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
19,383,975	1,239,248	1,445,722	19,698
87.83%	5.62%	6.55%	

Further Information:

- The Board (other than Ms Lil Bianchi) unanimously recommends that Shareholders vote in favour of Item 5.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 6: Approval for the renewal of the 4DMedical Limited Long Term Incentive Plan and the proposed issue of securities under the plan

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:


“That, for the purposes of Listing Rule 7.2 (Exception 13(b)), sections 257B(1) and 259B(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the 4DMedical Limited Long Term Incentive Plan and for the Company to issue up to 19,544,190 Securities under the 4DMedical Limited Long Term Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
17,800,480	1,103,643	2,954,694	231,938
81.43%	5.05%	13.52%	

Further Information:

- The Board does not make a recommendation in respect of this item, given directors' eligibility to participate in the plan.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Poll





4D Medical Limited (ASX:4DX)
Extraordinary General Meeting
22 January 2024

Copyright ©4D Medical Limited 2024
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia

www.4dmedical.com

ABN 31 161 684 831

